New cocktail of drugs shows promise against tough blood cancer
NCT ID NCT06068621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of six drugs (venetoclax plus CACAG regimen) against the standard '3+7' chemotherapy in 200 adults newly diagnosed with acute myeloid leukemia. The goal was to see if the new combo leads to more complete remissions after one treatment course. The trial is complete, and results will show whether this approach is more effective and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax combined with azacytidine, cytarabine, aclacinomycin, chidamide, and granulocyte colony-stimulating factor
What this could lead to
If successful, this combination could offer a more effective first-line treatment option for acute myeloid leukemia, potentially improving remission rates.
What could go wrong
This is a Phase 2 trial, so results are preliminary. The combination may cause more side effects than standard therapy, and it is not yet proven to be better or safer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China